A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis.
antipsychotics
drug safety
lithium
pharmacovigilance
somnambulism
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
revised:
11
02
2021
received:
11
06
2020
accepted:
01
03
2021
pubmed:
14
3
2021
medline:
28
10
2021
entrez:
13
3
2021
Statut:
ppublish
Résumé
Antipsychotics and lithium are widely used in psychiatry, particularly in schizophrenia and bipolar disorders. Recently, some cases of somnambulism or sleep-related eating disorder (SRED) have been reported in patients treated with these drugs. This study investigated the risk of reporting somnambulism or SRED associated with the use of antipsychotics and lithium. The World Health Organization pharmacovigilance database (VigiBase), comprising >18 million adverse events, was queried. All somnambulism or SRED reports related to antipsychotics or lithium were identified. The association between antipsychotics or lithium and somnambulism or SRED was computed using the proportional reporting ratio (PRR) and information component. Among the 5784 cases reporting somnambulism or SRED, 508 suspected at least 1 antipsychotic or lithium. Most patients were aged 18-64 years (62.0%), and 37.0% were men. In most cases (77.6%), antipsychotic or lithium were the only drug class involved, and 53.3% of cases suspected quetiapine. Somnambulism was reported in 88.6% of cases and SRED in 18.1%. A significant association was found for second-generation antipsychotics (PRR 3.44, 95% confidence interval 3.13) and lithium (PRR 2.03, [1.22; 3.37]), but not for first-generation antipsychotics (PRR 0.99, [0.68; 1.44]). We found a significant signal of somnambulism or SRED related to second-generation antipsychotics and lithium. While case reports mentioned mostly quetiapine and olanzapine, almost all second-generation antipsychotics were associated with somnambulism or SRED.
Substances chimiques
Antipsychotic Agents
0
Lithium
9FN79X2M3F
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3971-3977Informations de copyright
© 2021 British Pharmacological Society.
Références
Zadra A, Desautels A, Petit D, Montplaisir J. Somnambulism: clinical aspects and pathophysiological hypotheses. Lancet Neurol. 2013;12(3):285-294.
Broughton RJ. Sleep disorders: disorders of arousal? Enuresis, somnambulism, and nightmares occur in confusional states of arousal, not in « dreaming sleep ». Science. 1968;159(3819):1070-1078.
Stallman HM, Kohler M, White J. Medication induced sleepwalking: A systematic review. Sleep Med Rev. 2018;37:105-113.
Food and Drug Administration. Certain Prescription Insomnia Medicines: New Boxed Warning - Due to Risk of Serious Injuries Caused by Sleepwalking, Sleep Driving and Engaging in Other Activities While Not Fully Awake. FDA [Internet]. 2019[cité 10 mai 2019]; Disponible sur:;30avr. https://www.fda.gov/safety/medical-product-safety-information/certain-prescription-insomnia-medicines-new-boxed-warning-due-risk-serious-injuries-caused
Poryazova R, Waldvogel D, Bassetti CL. Sleepwalking in patients with Parkinson disease. Arch Neurol. 2007;64(10):1524-1527.
Wong CK, Marshall NS, Grunstein RR, et al. Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012. J Clin Sleep Med. 2017;13(2):223-234.
Ben-Hamou M, Marshall NS, Grunstein RR, Saini B, Fois RA. Spontaneous adverse event reports associated with zolpidem in Australia 2001-2008. J Sleep Res. 2011;20(4):559-568.
Hafeez ZH, Kalinowski CM. Somnambulism induced by quetiapine: two case reports and a review of the literature. CNS Spectr. 2007;12(12):910-912.
Chiu Y-H, Chen C-H, Shen WW. Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):581-582.
Kolivakis TT, Margolese HC, Beauclair L, Chouinard G. Olanzapine-induced somnambulism. Am J Psychiatryjuill. 2001;158(7):1158.
Faridhosseini F, Zamani A. A case report of somnambulism associated with olanzapine. Iran J Psychiatry Behav Sci. 2012;6(1):72-74.
Tamanna S, Ullah MI, Pope CR, Holloman G, Koch CA. Quetiapine-induced sleep-related eating disorder-like behavior: a case series. J Med Case Reports. 2012;6:380.
Das P. A Case of Sleepwalking With Sleep-Related Eating Associated With Ziprasidone Therapy in a Patient With Schizoaffective Disorder. J Clin Psychopharmacol. 2016;36(4):393-394.
Lindquist M. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Inf J. 2008;42(5):409-419.
Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov. 2007;14(3):305-328.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533-542.
van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf févr. 2002;11(1):3-10.
Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf. 2002;25(6):393-397.
Sauter TC, Veerakatty S, Haider DG, Geiser T, Ricklin ME, Exadaktylos AK. Somnambulism: Emergency Department Admissions Due to Sleepwalking-Related Trauma. West J Emerg Med. 2016;17(6):709-712.
Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632-638.
Juszczak GR, Swiergiel AH. Serotonergic hypothesis of sleepwalking. Med Hypotheses. 2005;64(1):28-32.
Di Fabio N, Poryazova R, Oberholzer M, Baumann CR, Bassetti CL. Sleepwalking, REM sleep behaviour disorder and overlap parasomnia in patients with Parkinson's disease. Eur Neurol. 2013;70(5-6):297-303.
Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA. 2002;288(13):1588.
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-396.
Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891-898.
Raja M, Raja S. Sleepwalking in four patients treated with quetiapine. Psychiatr Danub. 2013;25(1):80-83.
Seeman MV. Sleepwalking, a possible side effect of antipsychotic medication. Psychiatry Q. 2011;82(1):59-67.
Arnaud M, Salvo F, Ahmed I, et al. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases. Drug Saf. 2016;39(3):251-260.
Pariente A, Avillach P, Salvo F, et al. Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf. 2012;35(10):855-864.
Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol. 2020;86(2):244-249.
Müller L, Noseda R, Bertoli R, Bissig M, Ceschi A. Off-label use of quetiapine in nursing homes: Does medical specialty of prescribing physicians play a role? Br J Clin Pharmacol. 2020.
Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJW, Yuen N. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157-166.